Ganoderma lucidum polysaccharide accelerates refractory wound healing by inhibition of mitochondrial oxidative stress in type 1 diabetes

Cell Physiol Biochem. 2012;29(3-4):583-94. doi: 10.1159/000338512. Epub 2012 Apr 3.

Abstract

Background/aims: Refractory wounds in diabetic patients constitute a serious complication that often leads to amputation with limited treatment regimens. The present study was designed to determine the protective effect of Ganoderma lucidum polysaccharide (Gl-PS) on diabetic wound healing and investigate underlying mechanisms.

Methods: Streptozotocin (STZ)-induced type 1 diabetic mice with full-thickness excisional wounds were intragastrically administered with 10, 50 or 250 mg/kg/day of Gl-PS.

Results: Gl-PS dose-dependently rescued the delay of wound closure in diabetic mice. 50 and 250 mg/kg/day of Gl-PS treatment significantly increased the mean perfusion rate around the wound in diabetic mice. Diabetic conditions markly increased mitochondrial superoxide anion (O(2)·(-)) production, nitrotyrosine formation, and inducible nitric oxide synthase (iNOS) activity in wound tissues, which were normalized with Gl-PS treatment. In diabetic wound tissues, the protein level of manganese superoxide dismutase (MnSOD) was unchanged whereas MnSOD activity was inhibited and its nitration was potentiated; Gl-PS administration suppressed MnSOD nitration and increased MnSOD and glutathione peroxidase (GPx) activities. Moreover, Gl-PS attenuated the redox enzyme p66Shc expression and phosphorylation dose-dependently in diabetic mice skin.

Conclusion: Gl-PS rescued the delayed wound healing and improved wound angiogenesis in STZ-induced type 1 diabetic mice, at least in part, by suppression of cutaneous MnSOD nitration, p66Shc and mitochondrial oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / pathology
  • Dose-Response Relationship, Drug
  • Glutathione Peroxidase / metabolism
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / therapeutic use
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mitochondria / metabolism
  • Nitric Oxide Synthase Type II / metabolism
  • Oxidative Stress*
  • Polysaccharides / administration & dosage
  • Polysaccharides / therapeutic use*
  • Reishi / chemistry*
  • Shc Signaling Adaptor Proteins / metabolism
  • Skin / drug effects
  • Skin / injuries
  • Skin / metabolism
  • Skin / pathology
  • Src Homology 2 Domain-Containing, Transforming Protein 1
  • Streptozocin / administration & dosage
  • Streptozocin / adverse effects
  • Superoxide Dismutase / metabolism
  • Tyrosine / analogs & derivatives
  • Tyrosine / metabolism
  • Wound Healing*

Substances

  • Hypoglycemic Agents
  • Polysaccharides
  • Shc Signaling Adaptor Proteins
  • Shc1 protein, mouse
  • Src Homology 2 Domain-Containing, Transforming Protein 1
  • 3-nitrotyrosine
  • Tyrosine
  • Streptozocin
  • Glutathione Peroxidase
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse
  • Superoxide Dismutase